PDF(Sci-hub)
Abstract：
Background: Cancer incidence and mortality rates keep rising globally. Coriolus versicolor and Ganoderma lucidum related natural products are commonly applied as a complementary therapeutic option for different stages and types of cancers. The aim of this study is to evaluate the efficacy and safety of the products for cancer therapy. Methods: Randomized controlled trials were identified by systematic search over seven databases from inceptions to May 10, 2019. Two independent reviewers extracted data and assessed the study quality. Meta-analyses were performed to pool hazard ratio (HR), risk ratio (RR), mean differences (MD), and 95% CI using random-effects models. The sources of heterogeneity were explored by subgroup analyses and sensitivity analyses. Publication bias was detected by Funnel plots, Begg\'s test, and Egger\'s test. Results: Twenty-three trials involving 4,246 cancer patients were included in this work. C. versicolor and G. lucidum related natural products were significantly associated with lower risks of mortality (HR: 0.82; 95% CI: 0.72, 0.94) and higher total efficacy (RR: 1.30; 95% CI: 1.09, 1.55), but not associated with control rate (RR: 1.05; 95% CI: 0.96, 1.14) compared with control treatment. There was no significant difference between C. versicolor related natural products and control treatment in the effect on relapse-free survival (HR: 1.19; 95% CI: 0.91, 1.55). Compared with control treatment, C. versicolor and G. lucidum related natural products had a favorable effect on elevated levels of CD3 (MD: 9.03%; 95% CI: 2.10, 16.50) and CD4 (MD: 9.2%; 95% CI: 1.01, 17.39), but had no effect on the levels of CD8 (MD: -5.52%; 95% CI: -23.17, 12.13), CD4/CD8 (MD: 0.73; 95% CI:-0.45, 1.91), or NK(MD: 5.87%; 95% CI: -1.06, 12.8). Conclusion: In this meta-analysis, we found that C. versicolor and G. lucidum related natural products might have potential benefits on the overall survival and quality of life in cancer patients.
摘要：
背景：全球癌症发病率和死亡率持续上升。云芝和灵芝相关的天然产物通常用作不同阶段和类型癌症的补充治疗选择。这项研究的目的是评估用于癌症治疗的产品的有效性和安全性。方法：通过系统搜索从2019年5月10日开始的七个数据库来确定随机对照试验。两名独立评审员提取数据并评估研究质量。对池风险比(HR)进行了荟萃分析，风险比(RR)，平均差异(MD)，和95%CI使用随机效应模型。通过亚组分析和敏感性分析探索异质性的来源。通过漏斗图检测到出版偏倚，Begg\'stest,和Egger的测试。结果：这项工作包括23项涉及4,246例癌症患者的试验。杂色梭菌和灵芝相关天然产物与较低的死亡风险(HR:0.82;95%CI:0.72,0.94)和较高的总疗效(RR:1.30;95%CI:1.09,1.55)显著相关。但与对照治疗相比，与控制率无关（RR：1.05；95％CI：0.96，1.14）。杂色念珠菌相关天然产物与对照治疗对无复发生存的影响无显著差异(HR:1.19;95%CI:0.91,1.55)。与对照治疗相比，杂色梭菌和灵芝相关天然产物对CD3(MD:9.03%;95%CI:2.10,16.50)和CD4(MD:9.2%;95%CI:1.01,17.39)水平升高有有利作用,但对CD8水平没有影响（MD：-5.52％；95％CI：-23.17，12.13），CD4/CD8（MD：0.73；95%CI：-0.45，1.91），或NK（MD：5.87%；95%CI：-1.06，12.8）。结论：在本荟萃分析中，我们发现,杂色梭菌和灵芝相关天然产物可能对癌症患者的总体生存和生活质量有潜在的益处.
